Relationship between biomarker expression and allelic alteration in esophageal carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 12, 2007, Pages 2303-2309

  Vegh, Irene ^a   De La Calle Santiuste, Angel ^a   Colina, Francisco ^a   Bor, Lázsló ^a   Bermejo, Clara ^a   Aragón, Ana ^a   Morán Jiménez, María José ^a   Gómez Cámara, Agustín ^a   De Salamanca, Rafael Enríquez ^a   Moreno González, Enrique ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Allelic alteration; Biomarker; Chromosome 17p; Esophagus tumor

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INTERSTITIAL COLLAGENASE; SIALYL LEWIS X ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ALLELE; ARTICLE; CHROMOSOME 17P; ENZYME IMMUNOASSAY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

EID: 36348938634     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04374.x     Document Type: Article

References (29)

1. Nagase H, Woesserner JF Jr. Matrix metalloproteinases. J. Biol. Chem. 1999 274 : 21491 4.
2. Yamashita K, Mori M, Kataoka A, Inoue H, Sugimachi K. The clinical significance of MMP-1 in oesophageal carcinoma. Br. J. Cancer 2001 84 : 276 82.
3. Murray GI, Duncan ME, O'Neil P. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 1998 185 : 256 61.
4. Mimori K, Mori M, Shiraishi T et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br. J. Cancer 1997 76 : 531 6.
5. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl Cancer Inst. 1997 89 : 1260 70.
6. Gomez DE, Alonso DF, Yoshiji H, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 1997 74 : 111 22.
7. Torzewski M, Sarbia M, Verreet P et al. The prognostic significance of epidermal growth factor receptor expression in squamous cell carcinomas of the oesophagus. Anticancer Res. 1997 17 : 3915 19.
8. Sanders DS, Wilson CA, Bryant FJ et al. Classification and localization of carcinoembryonic antigen (CEA) related antigen expression in normal oesophageal squamous mucosa and squamous carcinoma. Gut 1994 35 : 1022 5.
9. Morales-Gutierrez C, Vegh I, Colina F et al. Survival of patients with colorectal carcinoma: possible prognostic value of tissular carbohydrate antigen 19.9 determination. Cancer 1999 86 : 1675 81.
10. Walch AK, Zitzelsberger HF, Bruch J et al. Chromosomal Imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am. J. Pathol. 2000 156 : 555 66.
11. Mandart AM, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of oesophagus. Mutat. Res. 2000 462 : 335 42.
12. World Health Organization. International Classification of Malignant Tumors. Geneva : Springer, 1988.
13. Sobin LH, Wittekind CH, Akerley W. TNM Classification of Malignant Tumours, 6th edn. New York : Wiley-Liss 2002.
14. Sambrook J, Fritsch E, Manniatis T. Molecular Cloning: A Laboratory Manual. Clod Spring, NY : Harbor Laboratory Press, 1989.
15. Oliphant AR, Wright EC, Swensen J, Gruis NA, Goldgar D, Skolnick MH. Dinucleotide repeat polymorphism at the D17S513 locus. Nucl. Acids Res. 1989 19 : 4794.
16. Oliphant AR, Wright EC, Swensen J, Gruis NA, Goldgar D, Skolnick MH. Dinucleotide repeat polymorphism at the D17S514 locus. Nucl. Acids Res. 1989 19 : 4794.
17. Vegh I, De la-Cruz J, Navarro S et al. Colorectal cancer relapse: allelic alterations associated with tumour marker overexpression. Oncology 2003 65 : 146 51.
18. Vegh I, Sotelo T, Estenoz J, Fontanellas A, Navarro S, Millan I Enriquez de Salamanca R. Tumor cytosol carcinoembryonic antigen as prognostic parameter in non-small cell lung cancer. Tumori 2002 88 : 142 6.
19. Seiki M. Membrane-type-1 matrix metalloproteinase: a key enzyme for tumour invasion. Cancer Lett. 2003 194 : 1 11.
20. Ohashi K, Nemoto T, Nakamura K, Memori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type-1 matrix metalloproteinase in esophageal squamous cell carcinoma. Cancer 2000 88 : 2201 9.
21. Inada S, Koto T, Futami K, Arima S, Iwashita A. Evaluation of malignancy and prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg. Today 1999 29 : 493 503.
22. McKnight A, Marmell A, Shperling I. The role of carbohydrate antigen 19.9 as a tumour marker of oesophagus cancer. Br. J. Cancer 1989 60 : 249 51.
23. Oshiba G, Kijima H, Tanaka H et al. Frequent expression of sialyl Le (a) in human squamous cell carcinoma. Int. J. Oncol. 2000 17 : 701 5.
24. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA. Value of serial carcino-embryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer 1995 75 : 451 6.
25. Gion M, Tremolada C, Mione R et al. Tumor markers in squamous cell carcinoma of esophagus: immunometric assay in cytosol and membrane fraction. Int. J. Biol. Markers 1990 5 : 7 13.
26. Owonikoko T, Rees M, Gabbert HE, Sarbia M. Intratumoral genetic heterogeneity in Barrett adenocarcinoma. Am. J. Clin. Pathol. 2002 117 : 558 66.
27. Vissers KJ, Riegman PH, Alers JC, Tilanus HW, van Dekken H. Involvement of cancer-activating genes on chromosome 7 and 8 in oesophageal (Barrett's) in gastric cardio adenocarcinoma. Anticancer Res. 2001 21 : 3813 20.
28. Meltzer SJ, Yin J, Huang Y et al. Reduction to homozigosity involving p53 in esophageal cancers demonstrated by polymerase chain reaction. Proc. Natl Acad. Sci. USA 1991 88 : 4976 80.
29. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ. Clonal expansion and loss of heterozigosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J. Natl. Cancer Inst. 1999 91 : 2087 95.